Novozymes A/S (OTCMKTS:NVZMY) Stock Short Interest Report for October

Novozymes A/S (OTCMKTS:NVZMY) was the target of a significant increase in short interest during the month of October. As of October 15th, there was short interest totaling 11,391 shares, an increase of 1,986.3% from the September 30th total of 546 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily trading volume, of 47,751 shares, the short-interest ratio is currently 0.2 days.

Institutional Investors Weigh In On Novozymes A/S

A hedge fund recently raised its stake in Novozymes A/S stock. Elefante Mark B increased its holdings in Novozymes A/S (OTCMKTS:NVZMY) by 73.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,900 shares of the biotechnology company’s stock after purchasing an additional 2,500 shares during the period. Elefante Mark B’s holdings in Novozymes A/S were worth $371,000 as of its most recent SEC filing. 0.03% of the stock is currently owned by hedge funds and other institutional investors.

Novozymes A/S Trading Down 2.5%

Shares of NVZMY traded down $1.81 on Monday, hitting $70.12. 14,248 shares of the stock traded hands, compared to its average volume of 26,515. Novozymes A/S has a 1 year low of $49.90 and a 1 year high of $75.27. The stock’s 50 day moving average is $67.47 and its two-hundred day moving average is $62.46. The firm has a market capitalization of $29.07 billion, a P/E ratio of 44.38, a P/E/G ratio of 3.23 and a beta of 0.89. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 0.25.

Novozymes A/S (OTCMKTS:NVZMY) last released its earnings results on Thursday, August 20th. The biotechnology company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.60 by ($0.16). The firm had revenue of $1.30 billion during the quarter, compared to analysts’ expectations of $1.27 billion. Novozymes A/S had a return on equity of 6.54% and a net margin of 14.70%. As a group, sell-side analysts predict that Novozymes A/S will post 2.45 earnings per share for the current year.

Novozymes A/S Company Profile

Novozymes A/S was a Denmark-based biotechnology company that developed and commercialized enzymes, microorganisms and other biological solutions for industrial and consumer applications. Its products were designed to help customers improve manufacturing processes, reduce resource consumption and develop more sustainable alternatives to conventional chemicals and production methods.

The company served a broad range of industries, including food and beverages, household care, agriculture, animal health, bioenergy and industrial manufacturing.